258 related articles for article (PubMed ID: 38205365)
1. Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment.
Ngo HKC; Le H; Surh YJ
J Cancer Prev; 2023 Dec; 28(4):131-142. PubMed ID: 38205365
[TBL] [Abstract][Full Text] [Related]
2. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
3. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
4. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
5. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
[TBL] [Abstract][Full Text] [Related]
6. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
Dempke WCM; Reck M
Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
[TBL] [Abstract][Full Text] [Related]
7. Insights into the New Cancer Therapy through Redox Homeostasis and Metabolic Shifts.
Hyun DH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645959
[TBL] [Abstract][Full Text] [Related]
8. "NRF2 addiction" in lung cancer cells and its impact on cancer therapy.
Hammad A; Namani A; Elshaer M; Wang XJ; Tang X
Cancer Lett; 2019 Dec; 467():40-49. PubMed ID: 31574294
[TBL] [Abstract][Full Text] [Related]
9. Nuclear Factor Erythroid 2-Related Factor 2/Kelch-Like ECH-Associated Protein 1 as a Predictor of Prognosis and Radiotherapy Resistance in Patients With Locally Advanced Rectal Cancer: A Prospective Analysis.
Park JM; Kim S; Bae SU; Byun SJ; Seo I; Lee HW
J Korean Med Sci; 2023 Jul; 38(26):e200. PubMed ID: 37401495
[TBL] [Abstract][Full Text] [Related]
10. The involvement of NRF2 in lung cancer.
Bauer AK; Hill T; Alexander CM
Oxid Med Cell Longev; 2013; 2013():746432. PubMed ID: 23577226
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms Underlying Hepatocellular Carcinoma Induction by Aberrant NRF2 Activation-Mediated Transcription Networks: Interaction of NRF2-KEAP1 Controls the Fate of Hepatocarcinogenesis.
Haque E; Karim MR; Salam Teeli A; Śmiech M; Leszczynski P; Winiarczyk D; Parvanov ED; Atanasov AG; Taniguchi H
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751080
[TBL] [Abstract][Full Text] [Related]
12. Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?
Wang R; Liang L; Matsumoto M; Iwata K; Umemura A; He F
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830722
[TBL] [Abstract][Full Text] [Related]
13. Myopathic lamin mutations cause reductive stress and activate the nrf2/keap-1 pathway.
Dialynas G; Shrestha OK; Ponce JM; Zwerger M; Thiemann DA; Young GH; Moore SA; Yu L; Lammerding J; Wallrath LL
PLoS Genet; 2015 May; 11(5):e1005231. PubMed ID: 25996830
[TBL] [Abstract][Full Text] [Related]
14. Functional Gene Knockout of
Bialk P; Wang Y; Banas K; Kmiec EB
Mol Ther Oncolytics; 2018 Dec; 11():75-89. PubMed ID: 30505938
[TBL] [Abstract][Full Text] [Related]
15. Carbosilane Dendrimers Loaded with siRNA Targeting Nrf2 as a Tool to Overcome Cisplatin Chemoresistance in Bladder Cancer Cells.
Ambrosio L; Argenziano M; Cucci MA; Grattarola M; de Graaf IAM; Dianzani C; Barrera G; Sánchez Nieves J; Gomez R; Cavalli R; Pizzimenti S
Antioxidants (Basel); 2020 Oct; 9(10):. PubMed ID: 33066634
[TBL] [Abstract][Full Text] [Related]
16. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
17. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
19. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
20. H-Ras induces Nrf2-Pin1 interaction: Implications for breast cancer progression.
Saeidi S; Kim SJ; Han HJ; Kim SH; Zheng J; Lee HB; Han W; Noh DY; Na HK; Surh YJ
Toxicol Appl Pharmacol; 2020 Sep; 402():115121. PubMed ID: 32621833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
